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DHBP, 3,4-dihydroxy-2-butanone 4-phosphate 
DMAPP, dimethylallyl pyrophosphate 
DMRL, 6,7-dimethyl-8-(1-D-ribityl)lumazine 
FMN, flavin mononucleotide  
FPPS, farnesyl pyrophosphate synthase 
GEM T cell, germline-encoded mycolyl lipid-reactive T cell 
HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate 
iNKT cell, invariant natural killer T cell 
IPP, isopentenyl pyrophosphate 
MAIT cell, mucosal-associated invariant T cell 
MEP, 2-C-methyl-D-erythritol 4-phosphate. 
MHC, major histocompatibility complex 
MR1, major histocompatibility complex class I-related protein 1 
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ABSTRACT 
Human Vγ9/Vδ2 T cells, mucosal-associated invariant T (MAIT) cells and other unconventional T cells 
are specialised in detecting microbial metabolic pathway intermediates that are absent in humans.  
The recognition by such semi-invariant innate-like T cells of compounds like (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate (HMB-PP), the penultimate metabolite in the MEP isoprenoid biosynthesis 
pathway, and intermediates of the riboflavin biosynthesis pathway and their metabolites allows the 
immune system to rapidly sense pathogen-associated molecular patterns that are shared by a wide 
range of micro-organisms.  Given the essential nature of these metabolic pathways for microbial 
viability, they have emerged as promising targets for the development of novel antibiotics.  Here, we 
review recent findings that link enzymatic inhibition of microbial metabolism with alterations in the 
levels of unconventional T cell ligands produced by treated micro-organisms that have given rise to 
the concept of ‘immuno-antibiotics’: combining direct antimicrobial activity with an 
immunotherapeutic effect via modulation of unconventional T cell responses. 
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MAIN TEXT 
Unconventional T cells represent a class of T cells that — unlike conventional CD4+ and CD8+ T cells 
— play a crucial role in sensing danger in the absence of classical restriction via the major 
histocompatibility complex (MHC).  Unconventional T cells comprise both αβ and γδ T cells that 
survey peripheral tissues and respond to stress-related changes upon infection, injury and 
malignancy.  In some instances, such responses include the recognition of non-peptidic antigens, 
typically in the context of members of the CD1 family or the MHC-related protein MR1, or via others 
factors such as butyrophilins [0].  There are two well-characterised populations of unconventional T 
cells which stand out with regard to their relative abundance in the human body, their broad 
reactivity toward microbial metabolites shared by a wide range of pathogens, and their ease of 
manipulation in vitro: Vγ9/Vδ2 T cells (also called V2/V2 T cells according to an alternative 
nomenclature) and mucosal-associated invariant T (MAIT) cells [2].  Moreover, there is the possibility 
of a compensatory interplay between these two types of unconventional T cells, as suggested from 
findings in an immunocompromised patient lacking functional MAIT cells, a result of a rare mutation 
in MR1, who instead showed highly elevated levels of circulating Vγ9/Vδ2 T cells *3].  In the 
following, we review progress and prospects for targeting microbial metabolic pathways for both 
direct as well as indirect, unconventional T cell-based killing of pathogens, as well as 
immunomodulation in general. 
‘Phosphoantigen’-reactive γδ T cells.  Vγ9/Vδ2 T cells are the dominant population of γδ T cells in 
human blood where they typically constitute 1-5% of all circulating T cells, but this can increase to 
>20-40% in many infections [4].  They are characterised by a distinct T cell receptor (TCR) composed 
of a semi-invariant Vγ9-JP (TRVG9–TRJP) chain and a highly diverse Vδ2 (TRVD2) chain.  Intriguingly, 
Vγ9/Vδ2 T cells have only been found in higher primates and alpacas, being absent in all other 
animal species studied so far [5].  They respond rapidly to intermediates of the isoprenoid 
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pyrophosphate (HMB-PP), which bind to the intracellular B30.2 domain of butyrophilin BTN3A1 
[6,7,8].  It is thought that this interaction induces a conformational change of the intracellular part of 
the protein and that this modified BTN3A1, and the related butyrophilin BTN2A1 — possibly 
together with as yet unknown cellular product(s) — form a complex on the cell surface that triggers 
the TCR-mediated activation of Vγ9/Vδ2 T cells *5,9].  As such, IPP and HMB-PP are not TCR ligands 
themselves but rather facilitate BTN2A1/BTN3A1-dependent γδ T cell responses toward microbial 
infections, in a truly unconventional fashion compared to ‘classical’ antigens.  The precise 
mechanism of this enigmatic recognition is yet to be unveiled.  
HMB-PP generation by micro-organisms.  HMB-PP is a highly immunogenic intermediate of the so-
called non-mevalonate (or MEP, after its signature metabolite 2-C-methyl-D-erythritol 4-phosphate) 
pathway of isoprenoid biosynthesis that is utilised by a wide range of Gram-negative and Gram-
positive bacteria but not by some bacterial pathogens, such as Staphylococcus spp. and 
Streptococcus spp., and yeasts [10].  Of note, the MEP pathway is also present in the chloroplasts of 
plants and in the plastid-like organelles of apicomplexan parasites, such as Plasmodium falciparum 
and Toxoplasma gondii, but is absent in animals. 
The MEP pathway starts from the condensation of pyruvate and glyceraldehyde 3-phosphate 
(Figure 1) and proceeds via the key enzymes 1-deoxy-D-xylulose 5-phosphate (DOXP) 
reductoisomerase (Dxr), HMB-PP synthase (IspG/GcpE) and HMB-PP reductase (IspH/LytB), yielding a 
mixture of the end products IPP and dimethylallyl pyrophosphate (DMAPP) in a ~5:1 ratio [10].  IPP 
and DMAPP are the building blocks of all higher isoprenoids, which include ubiquinone and 
menaquinone, essential for electron transport and ATP generation, as well as in bacteria long chain 
isoprenyl pyrophosphates such as undecaprenyl pyrophosphate, essential for cell wall 
(peptidoglycan) biosynthesis.  Since it is absent in humans, the MEP pathway has, therefore, 











adv/ltab005/6211066 by guest on 07 April 2021
The MEP pathway as drug target.  Historically, the best characterised target in the MEP pathway is 
DOXP reductoisomerase (Dxr), with the inhibitor fosmidomycin entering clinical trials against urinary 
tract infections in the mid 1980s [13], and against malaria, since 2003 [14].  Subsequent studies have 
also demonstrated the efficacy of fosmidomycin against multidrug-resistant bacteria [15].  Despite 
only having been discovered relatively recently, the crystal structures of all seven enzymes of the 
MEP pathway have been solved, often from more than one organism, and the enzymatic reactions 
they catalyse have been fully elucidated [16].  As a result, inhibitors of each enzyme have been 
characterised, and some of these compounds have been shown to inhibit bacteria and/or malaria 
parasites in vitro [17,18,19,20,21].  More recently, Singh et al. [22] showed the efficacy of novel IspH 
inhibitors against pan-resistant or multidrug-resistant strains of Acinetobacter baumannii, 
Enterobacter aerogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa and Vibrio cholerae in 
vitro, and against Enterobacter aerogenes in mice, and importantly, these compounds also affect the 
immune system: ‘immuno-antibiotics’ *23].  
Genetic manipulation of HMB-PP biosynthesis.  Given the importance of the MEP pathway for the 
generation of the γδ T cell activator HMB-PP, any manipulation of the pathway that results in an 
alteration of HMB-PP production is likely to have an impact on the corresponding Vγ9/Vδ2 T cell 
response, as summarised in Table 1.  For example, targeted deletion of genes encoding enzymes 
upstream of the generation of HMB-PP leads to a drastically reduced capacity of bacterial mutants to 
activate Vγ9/Vδ2 T cells *24,25,26,28].  In contrast, overexpression of Dxs [29] or IspG [29,30,31] 
enhances the metabolic flux through the pathway, thereby increasing HMB-PP levels, as does the 
targeted deletion of IspH [22,25,28,32,33], with HMB-PP accumulating and leading to Vγ9/Vδ2 T cell 
stimulation.  This correlation between bacterial HMB-PP levels and the ensuing γδ T cell response is 
true not only in vitro but has also been demonstrated in animal models in which deletion of IspG in 
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Listeria [26,27+, while deletion of IspH resulted in enhanced γδ T cell responses to E. coli in 
humanised mice [28] and to Salmonella enterica in rhesus macaques [33].   
Modulation of γδ T cell responses by immuno-antibiotics.  The findings with genetically engineered 
bacteria hold true for the pharmacological inhibition of the MEP pathway.  For example, inhibition of 
Dxr using fosmidomycin abrogated Vγ9/Vδ2 T cell responses to E. coli [34], Enterobacter cloacae [31] 
and Plasmodium falciparum in vitro [35,36], while inhibition of IspH increased anti-microbial 
Vγ9/Vδ2 T cell responses to E. coli, Mycobacterium smegmatis and Vibrio cholerae in vitro, and to E. 
coli in humanised mice [22].  Based on these observations, the MEP pathway not only constitutes a 
promising target for antimicrobial and antimalarial therapy [21,37,38], but also allows for the 
possibility of developing antibiotics that deliberately modulate Vγ9/Vδ2 T cell responses as a second 
effect (Table 1).  Depending on the enzymatic target, this may either result in silencing microbe-
responsive Vγ9/Vδ2 T cells — for instance, when using fosmidomycin — or in ‘turbo-charging’ 
Vγ9/Vδ2 T cells, as in the case of IspH inhibitors. 
Which of these two options is most desirable depends on the clinical context.  In vulnerable 
individuals such as patients with chronic kidney disease who depend on peritoneal dialysis as a life-
saving renal replacement therapy, any inflammation-related damage to the peritoneal membrane 
will negatively affect short and long-term clinical outcomes, so the possibility of silencing pro-fibrotic 
Vγ9/Vδ2 T cell responses during episodes of acute bacterial peritonitis might be an attractive option 
[39].  Similarly, particular attention needs to be paid to the protection of other organs that are prone 
to inflammation-related damage to the lungs, eyes, brain or reproductive organs.  Notwithstanding 
this potential risk, boosting γδ T cell responses towards microbial pathogens is likely to be beneficial 
in clearing many infections, as shown in humanised mice where a productive Vγ9/Vδ2 T cell 
expansion was associated with far lower bacterial loads in different organs [22].  In support of a 
protective role, adoptive transfer of Vγ9/Vδ2 T cells to Mycobacterium tuberculosis-infected 
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the tuberculosis-associated pathology [40].  Moreover, a modified Salmonella vaccine strain 
harbouring a deletion of IspH, thereby stimulating Vγ9/Vδ2 T cells better than the parental strain, 
was considered safe with no apparent side effects, in rhesus macaques [33].  It is thinkable that 
harnessing HMB-PP specific Vγ9/Vδ2 T cells using immuno-antibiotics may in fact boost memory-like 
recall responses to reinfection by HMB-PP producing organisms, and contribute to cross-protection 
against unrelated microbial species [41]. 
Inhibition of the classical isoprenoid pathway in humans and microbes.  IPP is present in all cells 
and is generated either from HMB-PP via the MEP pathway or, in organisms that do not produce 
HMB-PP (including humans), via the classical mevalonate pathway [10,12].  Free IPP is about 10,000 
fold less active than is HMB-PP in stimulating Vγ9/Vδ2 T cells in culture [10], and about 1,000 fold 
less active in binding to the purified BTN3A1 protein [6,8].  Despite this low bioactivity in vitro, IPP 
may still play a physiological role as a Vγ9/Vδ2 T cell activator by indicating the metabolic status of 
host cells.  In fact, pharmacological inhibition of downstream enzymes of the mevalonate pathway 
that increases intracellular IPP levels readily triggers Vγ9/Vδ2 T cell responses toward treated cells.  
The most studied examples are with the enzyme farnesyl pyrophosphate synthase (FPPS) that 
condenses two IPP molecules with one DMAPP to produce the C15 species, farnesyl pyrophosphate.  
Inhibiting the expression of FPPS [42], or blocking its activity using aminobisphosphonates such as 
pamidronate or zoledronate [43,44], leads to accumulation of IPP and DMAPP, both of which 
activate Vγ9/Vδ2 T cells.  Aminobisphosphonates are widely used in the clinic to treat excessive 
bone resorption in patients with osteoporosis and cancer [45], and because of their potential to 
induce Vγ9/Vδ2 T cell expansion in vitro and in vivo they are being exploited as novel 
immunotherapeutics [46,47].  While these drugs are generally considered safe, it remains unclear 
how Vγ9/Vδ2 T cells distinguish between metabolically active tissues that may contain elevated IPP 
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mevalonate pathway, such as steroid hormone producing glands and the liver, a major cholesterol 
producer in the body. 
Since the mevalonate pathway is also used by bacteria of clinical relevance, such as 
Staphylococcus aureus, and the bacterial enzymes are sufficiently distinct structurally from their 
mammalian counterparts, inhibitors of the bacterial isoprenoid biosynthesis are of increasing 
interest as candidates for novel classes of antibiotics targeting isoprenoid virulence factors and cell 
wall biosynthesis inhibitors [48,49].  Whether these inhibitors lead to an accumulation of upstream 
intermediates including IPP in treated bacteria, and hence an increased capacity to stimulate 
Vγ9/Vδ2 T cells, thus evoking the effect of aminobisphosphonates on human cells, remains to be 
determined. 
Immunological consequence of manipulating the riboflavin biosynthesis pathway.  Vγ9/Vδ2 T cells 
are not the only unconventional human T cells that recognise microbial metabolites.  Another well-
described antimicrobial T cell population are MAIT cells that recognise intermediates of the 
microbial riboflavin (vitamin B2) biosynthesis pathway presented by the MHC-related molecule MR1 
[50].  While the majority of bacteria and fungi possesses the riboflavin biosynthesis pathway, 
prominent exceptions being Streptococcus spp. and Enterococcus spp., it is essential and is notably 
absent in humans and other animals, so constitutes a potential drug target [51,52,53].  By analogy to 
the MEP pathway, the riboflavin biosynthesis pathway can be interrupted at various steps that are 
upstream or downstream of the generation of the potent MAIT cell ligand, 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) [50] (Figure 2).  In fact, genetic deletion of 
the enzymes mediating early steps in the pathway has been shown to abrogate MAIT cell responses 
to Lactococcus lactis, E. coli and Salmonella typhimurium in vitro [54,55,56] and to E. coli and 
Salmonella typhimurium in experimental mouse models in vivo [55,56,57], mimicking the effect of 
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The final two steps in the generation of riboflavin are the condensation of 5-amino-6-D-
ribitylaminouracil (5-A-RU) and 3,4-dihydroxy-2-butanone 4-phosphate (DHBP) to form 6,7-dimethyl-
8-(1-D-ribityl)lumazine (DMRL), catalysed by lumazine synthase (RibE in E. coli, RibH in some other 
bacteria), followed by the dismutation of two DMRL molecules into riboflavin and 5-A-RU, catalysed 
by riboflavin synthase (RibC).  The MAIT cell ligand 5-OP-RU is not an actual intermediate in the 
riboflavin biosynthesis pathway but rather, is generated when 5-A-RU reacts with methylglyoxal, an 
endogenous metabolite in mammalian cells and also a constituent in some dietary sources [58].  
Evoking the accumulation of HMB-PP in the MEP pathway either by genetic manipulation or via IspH 
inhibition [22,32], similar effects in the riboflavin biosynthesis pathway might lead to the 
accumulation of upstream intermediates including 5-A-RU and DMRL, and to concomitant MAIT cell 
activation.  Indeed, interruption of the terminal step of the pathway can lead to enhanced levels of 
DMRL in some bacteria, as shown for riboflavin synthase deficient Bacillus subtilis [59].  However, 
things are a little more complicated.  Specifically, genetic knockout of GTP cyclohydrolase II (RibA) or 
pyrimidine deaminase/reductase (RibD/RibG) abrogated 5-OP-RU formation and MAIT cell activation 
by E. coli and Lactococcus lactis, as expected, but DHBP synthase (RibB) or lumazine synthase 
(RibE/RibH) knockouts did not show enhanced 5-OP-RU levels or enhanced MAIT cell activation, 
compared to wildtype bacteria (Table 2) [54,55].  
A possible reason for these observations is that in order to grow, all of these knockouts 
require the addition of riboflavin to the medium [54,55,59], and high concentrations of riboflavin are 
known to trigger the so-called flavin mononucleotide (FMN) riboswitch — a genetic element that in 
many bacteria controls the expression of genes responsible for riboflavin biosynthesis by causing 
premature termination of the transcription of the rib operon [60,61].  Thus, a partial shutdown of 
the pathway via the FMN riboswitch in the presence of exogenous riboflavin would be expected to 
decrease the anticipated accumulation of intermediates such as 5-A-RU and DMRL, depending on 










adv/ltab005/6211066 by guest on 07 April 2021
class of antibiotics that lead to riboflavin starvation [62], and that are thus also likely to reduce MAIT 
cell activation.  The conclusion is, therefore, that unlike the situation with IspH — if we are to apply 
the concept of immuno-antibiotics to the riboflavin biosynthesis pathway — then enzymatic 
inhibition of DHBP synthase (RibB), riboflavin synthase (RibC) and/or lumazine synthase (RibE/RibH), 
rather than their genetic deletion, will be required.  In this respect, it is interesting to note that pre-
treatment with the pesticide chlorpyrifos has been shown to enhance the potential of E. coli to 
activate MAIT cells and that this effect appears to be accompanied by a reduced expression of 
riboflavin synthase [63].   
Targeting other microbe-responsive unconventional T cells.  Further candidates for immuno-
antibiotics include inhibitors of mycolic acid biosynthesis in mycobacteria, already an attractive 
target for novel tuberculosis drugs [64,65,66,67], since this is likely to affect the response of CD1b-
restricted germline-encoded mycolyl lipid-reactive (GEM) T cells [68].  Similarly, interruption of 
mycobacterial phosphomycoketide biosynthesis [69,70] might also affect antimicrobial responses by 
CD1c-restricted T cells [71].  Another well characterised population of unconventional T cells are 
CD1d-restricted invariant natural killer T (iNKT) cells, which are activated by glycolipids, especially 
microbial α-linked glycosphingolipids [72].  Altered iNKT cell activation as a consequence of 
interference with bacterial metabolism has not yet been described, although this may just be a 
consequence of our limited knowledge of the details of α-glycosphingolipid biosynthesis [73].  
Additional unconventional T cell populations with antimicrobial reactivity exist but are often only 
poorly characterised. 
Outlook.  Taken together, recent progress in our understanding of the MEP isoprenoid and riboflavin 
biosynthesis pathways has opened up new possibilities in targeting microbial pathogens.  This is all 
the more important in the current era of rapidly growing multidrug resistance to existing treatments, 
and a worrying shortage of new antibiotics in preclinical and clinical development.  Most intriguingly, 
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development of new immunotherapies that deliberately exploit this relationship, by using bespoke 
‘immuno-antibiotics’ that target pathogens both directly, by interrupting biosynthesis of vital 
metabolites, and indirectly, by harnessing the immune system against the infectious agent.  
However, it will be pivotal to minimise possible side effects such as overshooting responses that may 
cause local or systemic tissue damage.  Of particular interest will be answering the question as to 
whether specifically activating Vγ9/Vδ2 T cells, or other unconventional T cells, using such ‘immuno-
antibiotics’ confers long-lasting protection against reinfection with the same pathogen, or even 
against other microbes producing the same type of unconventional T cell ligands [27,41].  
Undoubtedly, new opportunities will become ever more apparent as we learn more about the 
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Table 1.  Immunological consequence of manipulating the MEP pathways of isoprenoid biosynthesis. 
Organism Target enzyme Type of manipulation 
Effect on γδ T cell 
response Experimental model Ref. 
Plasmodium falciparum Dxr Inhibition Reduction ↘ in vitro 35, 36 
E. coli Dxr Genetic deletion Reduction ↘ in vitro 24, 28 
E. coli Dxr Inhibition Reduction ↘ in vitro 31, 34  
E. coli IspG (GcpE) Genetic deletion Reduction ↘ in vitro 24, 28 
E. coli IspH (LytB) Genetic deletion Enhancement ↗ in vitro 22, 28, 32 
E. coli IspH (LytB) Inhibition Enhancement ↗ in vitro 22 
E. coli IspH (LytB) Genetic deletion Enhancement ↗ Hu-PBL-SCID/beige mice 28 
E. coli IspH (LytB) Inhibition Enhancement ↗ Hu-PBL-NSG mice 22 
Listeria innocua IspG (GcpE) Overexpression Enhancement ↗ in vitro 30, 31 
Listeria monocytogenes IspG (GcpE) Genetic deletion Reduction ↘ in vitro 25, 26 
Listeria monocytogenes IspG (GcpE) Genetic deletion Reduction ↘ Rhesus macaques 26, 27 
Listeria monocytogenes IspH (LytB) Genetic deletion Enhancement ↗ in vitro 25 
Mycobacterium smegmatis IspG (GcpE) Overexpression Enhancement ↗ in vitro 31 
Mycobacterium smegmatis IspH (LytB) Inhibition Enhancement ↗ in vitro 22 
Mycobacterium tuberculosis Dxs Overexpression Enhancement ↗ in vitro 29 
Mycobacterium tuberculosis Dxr Overexpression No effect — in vitro 29 
Mycobacterium tuberculosis IspG (GcpE) Overexpression Enhancement ↗ in vitro 29 
Salmonella enterica ser. Typhimurium IspH (LytB) Genetic deletion Enhancement ↗ in vitro 33 
Salmonella enterica ser. Typhimurium IspH (LytB) Genetic deletion Enhancement ↗ Rhesus macaques 33 
Vibrio cholera IspH (LytB) Inhibition Enhancement ↗ in vitro 22 
Hu-PBL-SCID/beige: Mice displaying severe combined immunodeficiency (SCID) affecting both B and T cells and carrying the beige mutation resulting in 
defective natural killer cells; reconstituted with human peripheral blood lymphocytes.  
Hu-PBL-NSG: Non-obese diabetic (NOD), severe combined immunodeficiency (SCID) and IL-2 receptor common gamma deficient mice lacking mature B, T and 
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Table 2.  Immunological consequence of manipulating the riboflavin pathway. 
Organism Target enzyme Type of manipulation 




E. coli GTP cyclohydrolase II (RibA) Genetic deletion Reduction ↘ in vitro 55* 
E. coli GTP cyclohydrolase II (RibA) Genetic deletion Reduction ↘ iVa19-Tg mice 55* 
E. coli 3,4-Dihydroxy-2-butanone 4-phosphate synthase (RibB) Genetic deletion No effect — in vitro 55* 
E. coli Pyrimidine deaminase/reductase (RibD) Genetic deletion Reduction ↘ in vitro 55* 
E. coli Pyrimidine deaminase/reductase (RibD) Genetic deletion Reduction ↘ iVa19-Tg mice 55* 
E. coli Pyrimidine deaminase/reductase (RibD) Genetic deletion Reduction ↘ C57BL/6 mice 57* 
E. coli Lumazine synthase (RibE) Genetic deletion No effect — in vitro 55* 
E. coli Lumazine synthase (RibE) Genetic deletion No effect — iVa19-Tg mice 55* 
E. coli n/a Chlorpyrifos treatment Enhancement ↗ in vitro 63* 
Lactococcus lactis GTP cyclohydrolase II (RibA) Genetic deletion Reduction ↘ in vitro 54 
Lactococcus lactis 3,4-Dihydroxy-2-butanone 4-phosphate synthase (RibB) Genetic deletion No effect — in vitro 54 
Lactococcus lactis Pyrimidine deaminase/reductase (RibG) Genetic deletion Reduction ↘ in vitro 54 
Lactococcus lactis Lumazine synthase (RibH) Genetic deletion No effect — in vitro 54 
Salmonella typhimurium Pyrimidine deaminase/reductase (RibD) 
and Lumazine synthase (RibH) 
Genetic deletion Reduction ↘ in vitro 54,56* 
Salmonella typhimurium Pyrimidine deaminase/reductase (RibD) 
and Lumazine synthase (RibH) 
Genetic deletion Reduction ↘ C57BL/6 mice 56* 
 
* Studies were performed using murine MAIT cells, which display the same MR1-dependent reactivity towards riboflavin metabolites as human MATI cells. 
iVa19-Tg: Mice expressing an invariant murine Vα19–Jα33 TCRα chain transgene. 
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FIGURES 
Figure 1.  Reaction steps of the MEP pathway of isoprenoid biosynthesis and generation of the 
Vγ9/Vδ2 T cell activator HMB-PP.  Red colour denotes the individual enzymes involved in the pathway; 
green arrows depict the targets of the Dxr inhibitors fosmidomycin and FR-900098, and the IspH 
inhibitors 2,4-dioxo-4-phenylbutanoate (C23.07) and 4-(2,5-dimethylphenyl)-4-oxobutanoate (C23.28). 
Enzymes: Dxs, 1-deoxy-D-xylulose 5-phosphate (DOXP) synthase; Dxr, DOXP reductoisomerase; IspD, 2-
C-methyl-D-erythritol 4-phosphate (MEP) cytidylyltransferase; IspE, 4-diphosphocytidyl-2-C-methyl-D-
erythritol kinase; IspF, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MEcPP) synthase; IspG, (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) synthase (GcpE); IspH, HMB-PP reductase 
(LytB).  
 
Figure 2.  Reaction steps of the riboflavin pathway and generation of the MAIT cell ligand 5-OP-RU.  
Red colour denotes the individual enzymes involved in the pathway.  Enzymes are labelled according to 
their names in E. coli; genes and enzymes in other bacteria such as Bacillus subtilis or Lactococcus lactis 
may follow a different nomenclature.  Note also that RibC catalyses the dismutation of two DMRL 
molecules. 
Enzymes: RibA, guanosine-5'-triphosphate (GTP) cyclohydrolase II; RibB, 3,4-dihydroxy-2-butanone 4-
phosphate (DHBP) synthase; RibC, riboflavin synthase; RibD, 2,5-diamino-6-(5′-phospho-D-
ribosylamino)-4-pyrimidinone (DARP) deaminase/reductase; RibE, 6,7-dimethyl-8-(1-D-ribityl)lumazine 
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